Business Description
Bioqual Inc
NAICS : 541713
SIC : 8731
ISIN : US09065J1016
Total Employee Number:
117Description
Bioqual Inc is a United States-based medical research company. It is engaged in providing contract research services focused on animal models of human diseases, including AIDS, influenza, RSV infection, flavivirus infections like Zika and Dengue, malaria, hepatitis, and cancer. The company is also involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. It provides services to the federal government, universities, and the life science and pharmaceutical industries. It derives revenue from the provision of contract research services.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.36 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.97 | |||||
Debt-to-EBITDA | 57.12 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 1.83 | |||||
Beneish M-Score | 0.35 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.2 | |||||
3-Year EBITDA Growth Rate | 60.6 | |||||
3-Year EPS without NRI Growth Rate | 107.1 | |||||
3-Year FCF Growth Rate | 51.4 | |||||
3-Year Book Growth Rate | 29.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-1 Month Momentum % | -13.36 | |||||
6-1 Month Momentum % | -15.58 | |||||
12-1 Month Momentum % | -24.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.41 | |||||
Quick Ratio | 4.41 | |||||
Cash Ratio | 2.13 | |||||
Days Sales Outstanding | 188.02 | |||||
Days Payable | 24.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 55.4 | |||||
3-Year Average Share Buyback Ratio | 0.3 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 9.03 | |||||
Operating Margin % | -4.46 | |||||
Net Margin % | -1.85 | |||||
EBITDA Margin % | 2.9 | |||||
FCF Margin % | -5.15 | |||||
OCF Margin % | -5.15 | |||||
ROE % | -1.08 | |||||
ROA % | -0.61 | |||||
ROIC % | -1.44 | |||||
3-Year ROIIC % | -30.21 | |||||
ROC (Joel Greenblatt) % | -2.3 | |||||
ROCE % | -1.62 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shiller PE Ratio | 41.53 | |||||
PS Ratio | 1.39 | |||||
PB Ratio | 0.81 | |||||
Price-to-Tangible-Book | 0.84 | |||||
EV-to-EBIT | -55.15 | |||||
EV-to-EBITDA | 84.82 | |||||
EV-to-Revenue | 2.46 | |||||
EV-to-FCF | -47.79 | |||||
Price-to-Projected-FCF | 1.17 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.32 | |||||
Earnings Yield (Greenblatt) % | -1.81 | |||||
FCF Yield % | -3.69 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BIOQ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bioqual Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20.834 | ||
| EPS (TTM) ($) | -0.43 | ||
| Beta | 0.0795 | ||
| 3-Year Sharpe Ratio | -1.39 | ||
| 3-Year Sortino Ratio | -1.52 | ||
| Volatility % | 14.2 | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | 0.028113 | ||
| 20-Day SMA ($) | 32.5 | ||
| 12-1 Month Momentum % | -24.75 | ||
| 52-Week Range ($) | 32.5 - 43.552 | ||
| Shares Outstanding (Mil) | 0.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioqual Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioqual Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| First quarter earnings results for 2027 | 2026-10-21 | In 99 days | ||
| General meeting for 2026 | 2026-09-25 | In 73 days | ||
| Annual report for 2026 | 2026-09-18 | In 66 days | ||
| Fourth quarter earnings results for 2026 | 2026-09-18 | In 66 days | ||
| Third quarter earnings results for 2026 | 2026-04-21 | 37.51 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-01-22 | 38.50 (+0.00%) | ||
| First quarter earnings results for 2026 | 2025-10-21 | 40.00 (+0.00%) | ||
| Annual report for 2025 | 2025-09-19 | 39.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2025-09-19 | 39.00 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-04-11 | 55.00 (+0.00%) |
Show
Entries
Bioqual Inc Frequently Asked Questions
What is Bioqual Inc(BIOQ)'s stock price today?
The current price of BIOQ is $32.50. The 52 week high of BIOQ is $43.55 and 52 week low is $32.50.
When is next earnings date of Bioqual Inc(BIOQ)?
The next earnings date of Bioqual Inc(BIOQ) is 2026-09-18 Est..
Does Bioqual Inc(BIOQ) pay dividends? If so, how much?
Bioqual Inc(BIOQ) does not pay dividend.
Guru Commentaries on OTCPK:BIOQ
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Bioqual Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers